LONGITUDINAL CAPACITY REPORT
M. SORENSON · MRN 40571-CGenerated Jul 16, 2026 · UnDun Health
PATIENT CAPACITY REVIEW
Morgan Sorenson
44 yrs · Male · Peptides (off-label) · Reporting period Apr–Jul 2026 (12 weeks)
Patient view ↗
COMPOSITE · vs BASELINE
+2.2%
▲ Improving · safety review
UNDUN INTELLIGENCE · SUMMARY
Composite is +2.2%, led by locomotion +7.2% during a shoulder-rehab block, but the gains coincide with a cardiovascular signal. The patient is self-sourcing BPC-157 off-label; resting heart rate is up +8 bpm and estimated blood pressure has trended up for three weeks.
FLAGGED THIS CYCLE
LOCOMOTION +7.2% RESTING HR +8 BPM
RECOMMENDED ACTION
Message the patient; discuss the off-label peptide and its source, and check blood pressure before continuing.
Concise view. Switch to Standard for domains and trajectory, or Comprehensive for the full workup: heat map, aging projection, intervention impact and labs.
Capacity by domain
| DOMAIN | vs BASELINE | 12-WK TREND | STATUS |
|---|---|---|---|
| Locomotion | +7.2% | improving | MEANINGFUL |
| Vitality | +1.8% | improving | STABLE |
| Psychological | +1.0% | holding | STABLE |
| Cognitive | +0.6% | holding | STABLE |
| Sensory | +0.2% | stable | STABLE |
Composite is the mean of the five domain scores, each expressed as percent from personal baseline.
Composite trajectory
Composite capacity, percent from personal baseline. Steady functional gain; cardiovascular signal emerges over the last three weeks.
INTERVENTION TIMELINE
Rehab block
Peptide
Suggested care plan
SAFETY REVIEW
UNDUN INTELLIGENCE · DECISION SUPPORT
Objective: Keep the functional gains while resolving the cardiovascular safety signal.
MEDICATION
Discuss the off-label peptide openly, including source and purity; consider pausing during evaluation.
MONITORING
Measure blood pressure in clinic and review home readings.
MONITORING
Track resting heart rate and HRV weekly.
FOLLOW-UP
Retest in 2 weeks.
DOCUMENTATION
Document shared decision-making given self-sourced therapy.
Draft plan generated by UnDun Intelligence. Requires clinician review and sign-off before it takes effect.
Signed Date
Wearable vitals
Resting heart rate+8 bpm
Estimated blood pressurerising
HRV (rMSSD)−6%
Sleep duration7.1 h
Data coverage91%
Active interventions
BPC-157 peptideOFF-LABEL / SELF-SOURCED
Not prescribed. Source and purity unverified. Timing aligns with RHR rise.
Shoulder rehab blockACTIVE
Adherence 90%. Driving the locomotion improvement.
Week-by-week detail
W1
W2
W3
W4
Composite
+1.0
+1.5
+1.9
+2.2
Locomotion
+3.2
+5.2
+6.2
+7.2
Vitality
+0.8
+1.3
+1.5
+1.8
Psychological
+0.5
+0.7
+0.9
+1.0
Cognitive
+0.3
+0.4
+0.5
+0.6
Sensory
+0.1
+0.1
+0.2
+0.2
Each domain by week, percent from baseline. Composite is the row mean.
Sleep & recovery
Avg sleep duration7.1 h
In range
Sleep consistency79%
Good
Deep sleep1.3 h
18% of night
REM sleep1.5 h
21% of night
Resting HR+8 bpm
Rising — watch
HRV (rMSSD)−6%
Dipping
Body composition & activity
Weight−1.2%
Stable
Lean mass+2.4%
Gaining
Body fat−2.0%
Down
Avg daily steps9,600
Strong
Zone 2 minutes168 / wk
Above target
Active days25 / 30
Consistent
Measured intervention effect
Composite capacity in the four weeks before versus after each intervention started, isolating its measured effect.
| INTERVENTION | 4-WK PRE | 4-WK POST | Δ |
|---|---|---|---|
| Zone 2 rehab block | +0.4% | +2.4% | +2.0% |
| BPC-157 peptide | — | — | confounded |
Projected intervention impact
Estimated effect of each lever at target adherence, with the projected years of function preserved. Illustrative, model-based projections.
LOCOMOTION · CARDIO
+9%
above baseline
5 yrs
delayed symptoms
Zone 2 rehab block
3× weekly Zone 2+6%
Weekly strength session+3%
SAFETY
+3%
above baseline
protective
risk reduction
Cardiovascular risk control
Blood-pressure normalization+2%
Off unverified peptide+1%
Domain heat map
On track
Watch
Concerning
Locomotion
Vitality
Psychological
Cognitive
Sensory
12 wk agonow
Weekly capacity status by domain, relative to personal baseline. Amber marks drift; red marks a crossed threshold.
Aging trajectory projection
YOUR TRAJECTORY
REFERENCE AGING
SYMPTOM THRESHOLD
If cardiovascular risk is controlled, the trajectory stays above threshold well past age 88.
Recent labs & biomarkers
| MARKER | VALUE | REF RANGE | FLAG |
|---|---|---|---|
| Hematocrit | 51% | 40–50 | HIGH |
| Testosterone | 1120 ng/dL | 300–1000 | HIGH |
| Blood pressure | 138/88 | <130/80 | HIGH |
| hs-CRP | 0.8 mg/L | <1.0 | — |
| ApoB | 82 mg/dL | <90 | — |
| eGFR | 95 | >60 | — |
Most recent panel on file. Flags are relative to standard reference ranges, not personalized targets.
Reviewing clinician: Dr. A. Okafor · UnDun Health. This report summarizes passively collected wearable and body-composition data interpreted against the patient's own baseline. UnDun Intelligence findings are decision-support hypotheses, not diagnoses, and do not replace clinical judgment.